RT @drminidey #OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile.